Pacira | PCRX - Operating Expenses


Pacira reported $1.18B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Astellas Pharma JPY 497.36B 41.8B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 18.93B 1.09B Sep/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novo Nordisk DKK 44.73B 7.52B Jun/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 1.18B 995.96M Sep/2026
Perrigo USD 961.4M 670.9M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Supernus Pharmaceuticals USD 1.06B 31.25M Sep/2026
Teva Pharmaceutical Industries USD 3.18B 733M Sep/2026
Xeris Pharmaceuticals USD 86.93M 11.72M Jun/2026
Zoetis USD 3.3B 155M Sep/2026